Researcher Spotlight: Niloufer Khan, MD CITY OF HOPE COMPREHENSIVE CANCER CENTER Health Equity Initiative Cutaneous T-cell lymphoma (CTCL) is a chronic form of cancer that causes pain, discomfort, and itchiness that can affect patients’ well-being and quality of life. “Itch…
Researcher Spotlight: Preteesh Jain, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chemotherapy-sparing treatment regimens are of great interest for many patients with lymphoma due to the variety of short- and long-term toxicities associated with These therapies. To this…
Researcher Spotlight: Preteesh Jain, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chemotherapy-sparing treatment regimens are of great interest for many patients with lymphoma due to the variety of short- and long-term toxicities associated with These therapies. To this…
Researcher Spotlight: Tomohiro Aoki, MD, PhD UNIVERSITY HEALTH NETWORK Peykoff Initiative Investigator Cancer cells exist within a greater tumor microenvironment that is modified by tumor cells to support their growth and proliferation. These cells can also modify their environment to…
Researcher Spotlight: Erin Parry, MD, PhD DANA-FARBER CANCER INSTITUTE Dr. Parry’s research is centered at the intersection of genomics and cancer immunotherapy, with a focus on B cell lymphomas. Her LRF research project is aimed at understanding the processes that…
Researcher Spotlight: Wen-Hsuan Wendy Lin, MD, PhD COLUMBIA UNIVERSITY Peripheral T-cell lymphomas (PTCL) represent a group of aggressive blood cancers with poor outcomes. A common phenomenon in PTCL is the development of a proinflammatory microenvironment, in which lymphoma cells recruit…
Researcher Spotlight: Andrew Jallouk, MD, PhD Vanderbilt University Medical Center Errol M. Cook Memorial Scholar Chimeric antigen receptor (CAR) T-cell therapy represents a highly effective treatment option for many types of lymphoma. Currently available CAR T-cell therapies are engineered on…
Researcher Spotlight: Alexander Boardman, MD Memorial Sloan Kettering Dobosh Family Scholar Treatment of lymphoma has been revolutionized by the emergence of CD19-directed chimeric antigen receptor (CAR) T-cell therapies, but many patients still relapse after treatment. Dr. Boardman’s LRF research seeks…
Researcher Spotlight: Ajilan Al Zaki, MD, PhD MD Anderson Cancer Center Chimeric antigen receptor (CAR) T-cell therapies represent a meaningful treatment option for lymphoma, but many patients who receive these therapies will experience side effects caused by inflammation. In some…
Researcher Spotlight: Timothy Voorhees, MD THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE Schroder Family Scholar Post-transplant lymphoproliferative disorders (PTLD) are an aggressive group of lymphomas that occur in the setting of immunosuppression after solid organ transplant. There are very few…